ResMed is a medical instruments & supplies business based in Australia. ResMed shares (RMD) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. ResMed has a trailing 12-month revenue of around $4.5 billion. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as ResMed, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.
Our top pick for
Best for beginner
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $21.0628 - $36.1293 |
|---|---|
| 50-day moving average | $27.933 |
| 200-day moving average | $26.6704 |
| Target price | $33.53 |
| PE ratio | 31.7283 |
| Dividend yield | $1.84 (0.99%) |
| Earnings per share (TTM) | $0.92 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$29.35
| 1 week (2024-03-19) | 0.65% |
|---|---|
| 1 month (2024-02-27) | 5.39% |
| 3 months (2023-12-27) | 15.32% |
| 6 months (2023-09-27) | 27.66% |
| 1 year (2023-03-27) | -8.45% |
|---|---|
| 2 years (2022-03-25) | -7.06% |
| 3 years (2021-03-26) | 17.97% |
| 5 years (2019-03-27) | 104.96% |
Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, ResMed shares trade at around 32x recent earnings.
That's comparable to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14).
ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.8593. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.4 billion (£0.0 million).
The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure stock profitability.
| Revenue TTM | $4.5 billion |
|---|---|
| Operating margin TTM | 29.18% |
| Gross profit TTM | $2.4 billion |
| Return on assets TTM | 11.19% |
| Return on equity TTM | 21.66% |
| Profit margin | 19.77% |
| Book value | 30.471 |
| Market capitalisation | $43.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 21.86% of net profits
Recently ResMed has paid out, on average, around 21.86% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.99% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 0.99% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about A$1.84 per share.
While ResMed's payout ratio might seem low, this can signify that ResMed is investing more in its future growth.
The latest dividend was paid out to all shareholders who bought their shares by 6 February 2024 (the "ex-dividend date").
ResMed's shares were split on a 2:1 basis on 11 August 2010. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your ResMed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ResMed shares which in turn could have impacted ResMed's share price.
Over the last 12 months, ResMed's shares have ranged in value from as little as $21.0628 up to $36.1293. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while ResMed's is 0.655. This would suggest that ResMed's shares are less volatile than average (for this exchange).
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
AMP Ltd Preferred
AUD104.82
ANZ Group Holdings Ltd. Pfd.
AUD101.63
Challenger Ltd Preferred
AUD104.67
Macquarie Bank Ltd Pref
AUD104.95
Macquarie Group Ltd Pref C
AUD103.59
Macquarie Group Ltd Pref
AUD105.65
Macquarie Group Preferred
AUD102.26
Macquarie Group Limited
AUD105.46
Suncorp Group Ltd Pref
AUD101.02
Everything we know about the D3 Energy IPO, plus information on how to buy in.
Steps to owning and managing Novo Resources Corp shares.
Here's all the key information you need to know to sell shares you inherited or received as a gift.
Pros and cons to consider before investing in Chinese stocks.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing NVIDIA shares from in Australia.
Steps to owning and managing Carnival shares from in Australia.
Find out what tax deductions you're entitled to if you’re a share trader or an investor.
Follow our guide to learn how to buy bonds – one of the top investment options available.
What are managed funds? Read our guide and learn the different types of managed funds available.